Invirsa
COLUMBUS, OH · Manufacturing · 9 employees
Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication. INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon,
Funding history
- Series seed — $2.9M — Aug 2025
- Funding Round — $2.8M — Aug 2025
- Series seed — $1000K — Nov 2023
- Funding Round — $6.0M — Dec 2022
- Series pre-seed — $2.9M — Dec 2020
Recent signals
- Aug 08, 2025: Raised $2.9M in Series seed
- Aug 06, 2025: Raised $2.8M
- Nov 29, 2023: Raised $1000K in Series seed
- Dec 29, 2022: Raised $6.0M
- Dec 11, 2020: Raised $2.9M in Series pre-seed
See plans & pricing → Track Invirsa’s funding, hiring, and signals — with verified contacts — on Fundz.